Nichi-Iko Of Japan Invests ¥7.3 Billion To Build New Production Facility
This article was originally published in PharmAsia News
Toyama-based generic drug maker Nichi-Iko Pharmaceutical announced it will build a new production facility in Katsukawa, Toyama prefecture. Chiyoda TechnoAce, a subsidiary of Yokohama-based Chiyoda Corp has been awarded the ¥7.3 billion construction contract. Construction starts this September and will be completed by October 2009. Actual production is expected to start in December 2009. The Japanese generics market has been growing and generics makers are speeding up facility investment and the integration of production and research facilities to boost efficiency. (Click here for more - Japanese language
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.